- Email: [email protected]
12 – Olanzapine and cerebral mechanism involved in appetite and weight gain in schizophrenia: An fMRI study
ABSTRACTS / Schizophrenia Research 98 (2008) 3–199 SCZ compared to 30% BP and 5% HC subjects. Among cognitively impaired SCZ subjects, more than half showed a decline from premorbid level, compared to one third of the cognitively impaired BP group. Of the neuropsychologically unimpaired subjects, 7% SCZ and 3% BP showed signs of reduced IQ performance from premorbid level. Conclusions: Neuropsychologically impairment is confirmed to be more frequent in SCZ than in BP subjects, although more then half of the SCZ and two-thirds BP subjects did not evidence any neurocognitive difficulties. Support for premorbid impairment as well as a worsening of cognitive performance was found in both groups. The study thus supports a combined neurodevelopmental and neurodegenerative model for cognitive impairment.
37
symptoms of schizophrenia when used by clinicians with minimal NSA-4 training. doi:10.1016/j.schres.2007.12.078
Bipolar/Schizophrenia Comparisons – fMRI and sMRI 12 – OLANZAPINE AND CEREBRAL MECHANISM INVOLVED IN APPETITE AND WEIGHT GAIN IN SCHIZOPHRENIA: AN FMRI STUDY
doi:10.1016/j.schres.2007.12.077 E. Stip 1,2, K. Anselmo 1, P. Dellamillieure 2,3, A. Mancini-Marie 1, A Mendrek 1, L. Ait Bentaleb 1, O. Lipp 1, M.C. Delisle 1, P. Lalonde 1, P. Léouffre 1, T. Pampoulova 1, S. Dollfus 2,3. 11 – USE OF THE 4-ITEM NEGATIVE SYMPTOM ASSESSMENT (NSA-4) BY MINIMALLY TRAINED CLINICIANS A. Van Willigenburg 1, L. Alphs 2, R. Morlock 2, J. Panagides 1. 1
Organon International Inc, Roseland, NJ, USA Employed at Pfizer Global R&D, Ann Arbor, MI, USA, at the time of this study 2
Presenting Author details: [email protected] 56 Livingston Ave, 07068 Roseland, United States, Tel.: +1 973 325 5347.
1
Department of Psychiatry, Fernand-Seguin Research Center, L-H. Lafontaine Hospital, University of Montreal, Montreal, Canada 2 Centre National de la Recherche Scientifique (CNRS), Centre Cyceron, Caen, France 3 Department of Psychiatry, Centre Hospitalier Universitaire (CHU Côte de Nacre), Caen, France Presenting Author details: [email protected] 7331 Rue Hochelaga, H1N 3V2 Montreal, Canada, Tel.: +1 514 251 4015; fax: +1 514 251 2617.
Methods: Participant ratings were compared to the consensus ratings from 2 experts involved in the development of the 16-item NSA classifications.
Background: Several antipsychotic treatments are associated with metabolic side effects and weight gain including olanzapine. The present study investigated the cerebral mechanisms by which olanzapine influences appetite and weight gain. Methods: Using functional magnetic resonance imaging (fMRI), 10 schizophrenia patients (SZ) and ten normal controls (NC), all righthanded, matched for age and sex, were scanned using during passive viewing of appetizing and neutral stimuli (film excerpts and pictures) before and after 16 weeks of treatment with olanzapine. Overtime changes in weight and body size and eating behavior were measured with the Three-Factor Eating Questionnaire (FTEQ) for all subjects. Patients were screened using Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale (CDS).
Results: Meeting participants provided ratings similar to those of the experts. For items with expert ratings of 4 (i.e. behavior is moderately reduced), 87%, 85%, and 87% of participants selected a rating within one category of 4 for reduced speech quantity, reduced emotion, and reduced interests, respectively. For items with expert ratings of 5 (i.e., behavior is severely reduced or entirely absent), 91% and 82% of the participants selected a rating within one category of 5 for reduced social drive and global negative symptoms, respectively.
Results: Following treatment with olanzapine, there was a significant increase in the abdominal circumference, weight gain and in the score of control disinhibition item of the FTEQ in the SZ group. Greater activations in the parietal (precuneus and angular gyrus) and occipital (cuneus) cortex were observed during exposure to appetizing stimuli in the SZ following the treatment with olanzapine. Direct within-group comparison revealed over-time treatment-related relative increases in activation in regions of the prefrontal, orbitofrontal, parietal and cingulate cortex, as well as the cerebellum.
Conclusions: High levels of consistency were obtained between ratings conducted by psychiatric meeting participants and experts after minimal training, with modal scores close to expert ratings and nearly all ratings falling within 1 point of the expert consensus. No meaningful scoring differences were found between US and non-US raters, psychiatrist and non-psychiatrist raters, experienced and inexperienced raters, or attendees of the APA and ECNP meetings. This study demonstrates that the NSA-4 is a valuable and easily used clinical instrument for assessing negative
Conclusions: These results suggest that olanzapine may be associated with control disinhibition of food intake and a significant weight gain via the mechanism of cerebral overactivation of regions implicated in the somatosensory and evaluative processing of appetitive stimuli.
Background: The 4-item Negative Symptom Assessment (NSA-4) is a new clinician-rated instrument designed to rapidly assess negative symptoms of schizophrenia. This study assessed the reliability of the NSA-4 when used by mental health professionals attending the American Psychiatric Association (APA) and the European College of Neuropsychopharmacology (ECNP) meetings in 2006.
doi:10.1016/j.schres.2007.12.079
37
symptoms of schizophrenia when used by clinicians with minimal NSA-4 training. doi:10.1016/j.schres.2007.12.078
Bipolar/Schizophrenia Comparisons – fMRI and sMRI 12 – OLANZAPINE AND CEREBRAL MECHANISM INVOLVED IN APPETITE AND WEIGHT GAIN IN SCHIZOPHRENIA: AN FMRI STUDY
doi:10.1016/j.schres.2007.12.077 E. Stip 1,2, K. Anselmo 1, P. Dellamillieure 2,3, A. Mancini-Marie 1, A Mendrek 1, L. Ait Bentaleb 1, O. Lipp 1, M.C. Delisle 1, P. Lalonde 1, P. Léouffre 1, T. Pampoulova 1, S. Dollfus 2,3. 11 – USE OF THE 4-ITEM NEGATIVE SYMPTOM ASSESSMENT (NSA-4) BY MINIMALLY TRAINED CLINICIANS A. Van Willigenburg 1, L. Alphs 2, R. Morlock 2, J. Panagides 1. 1
Organon International Inc, Roseland, NJ, USA Employed at Pfizer Global R&D, Ann Arbor, MI, USA, at the time of this study 2
Presenting Author details: [email protected] 56 Livingston Ave, 07068 Roseland, United States, Tel.: +1 973 325 5347.
1
Department of Psychiatry, Fernand-Seguin Research Center, L-H. Lafontaine Hospital, University of Montreal, Montreal, Canada 2 Centre National de la Recherche Scientifique (CNRS), Centre Cyceron, Caen, France 3 Department of Psychiatry, Centre Hospitalier Universitaire (CHU Côte de Nacre), Caen, France Presenting Author details: [email protected] 7331 Rue Hochelaga, H1N 3V2 Montreal, Canada, Tel.: +1 514 251 4015; fax: +1 514 251 2617.
Methods: Participant ratings were compared to the consensus ratings from 2 experts involved in the development of the 16-item NSA classifications.
Background: Several antipsychotic treatments are associated with metabolic side effects and weight gain including olanzapine. The present study investigated the cerebral mechanisms by which olanzapine influences appetite and weight gain. Methods: Using functional magnetic resonance imaging (fMRI), 10 schizophrenia patients (SZ) and ten normal controls (NC), all righthanded, matched for age and sex, were scanned using during passive viewing of appetizing and neutral stimuli (film excerpts and pictures) before and after 16 weeks of treatment with olanzapine. Overtime changes in weight and body size and eating behavior were measured with the Three-Factor Eating Questionnaire (FTEQ) for all subjects. Patients were screened using Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale (CDS).
Results: Meeting participants provided ratings similar to those of the experts. For items with expert ratings of 4 (i.e. behavior is moderately reduced), 87%, 85%, and 87% of participants selected a rating within one category of 4 for reduced speech quantity, reduced emotion, and reduced interests, respectively. For items with expert ratings of 5 (i.e., behavior is severely reduced or entirely absent), 91% and 82% of the participants selected a rating within one category of 5 for reduced social drive and global negative symptoms, respectively.
Results: Following treatment with olanzapine, there was a significant increase in the abdominal circumference, weight gain and in the score of control disinhibition item of the FTEQ in the SZ group. Greater activations in the parietal (precuneus and angular gyrus) and occipital (cuneus) cortex were observed during exposure to appetizing stimuli in the SZ following the treatment with olanzapine. Direct within-group comparison revealed over-time treatment-related relative increases in activation in regions of the prefrontal, orbitofrontal, parietal and cingulate cortex, as well as the cerebellum.
Conclusions: High levels of consistency were obtained between ratings conducted by psychiatric meeting participants and experts after minimal training, with modal scores close to expert ratings and nearly all ratings falling within 1 point of the expert consensus. No meaningful scoring differences were found between US and non-US raters, psychiatrist and non-psychiatrist raters, experienced and inexperienced raters, or attendees of the APA and ECNP meetings. This study demonstrates that the NSA-4 is a valuable and easily used clinical instrument for assessing negative
Conclusions: These results suggest that olanzapine may be associated with control disinhibition of food intake and a significant weight gain via the mechanism of cerebral overactivation of regions implicated in the somatosensory and evaluative processing of appetitive stimuli.
Background: The 4-item Negative Symptom Assessment (NSA-4) is a new clinician-rated instrument designed to rapidly assess negative symptoms of schizophrenia. This study assessed the reliability of the NSA-4 when used by mental health professionals attending the American Psychiatric Association (APA) and the European College of Neuropsychopharmacology (ECNP) meetings in 2006.
doi:10.1016/j.schres.2007.12.079